Tempus AI Surges 15% in Nasdaq Debut, Valuation Hits $7 Billion

The Google-backed health diagnostics company raised $410 million in its IPO, aiming to revolutionize precision medicine with AI.

Tempus AI priced its IPO at $37 per share, the top of its target range.
The company focuses on using AI to improve diagnostic accuracy and personalize medical treatments.
CEO Eric Lefkofsky expects Tempus to be cash flow and EBITDA positive within a year.
Tempus generated $531.8 million in revenue in 2023 but reported a net loss of $214.1 million.
Key investors include Google, SoftBank, and Franklin Templeton.